C4 Therapeutics, Roche Ink USD 1 Billion Cancer Drug Deal for Novel DAC Therapies
New Delhi: C4 Therapeutics, opens new tab said on Thursday it has entered into a deal focused on research and development of a type of cancer drug with Swiss drugmaker Roche, opens new tab that could be worth more than USD 1 billion.
- The companies will collaborate on two programs to develop degrader-antibody conjugates against undisclosed oncology targets exclusive to the agreement.
- Degrader-antibody conjugates (DAC) are an emerging class of cancer therapies that combine antibody-drug conjugation with targeted protein degradation technology.
- Roche will be responsible for advancing DAC candidates through preclinical and clinical development as well as commercialization.
- C4T will receive a $20 million upfront payment for the two programs. If Roche exercises its option for a third target, C4T will receive an additional payment.
- C4T is also eligible to receive over $1 billion in discovery, regulatory and commercial milestone payments, and entitled to tiered royalties on future sales.
- The agreement marks the third collaboration between the two companies and extends a relationship that began in 2016.
Next Story